The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Vivodyne, a Penn spinout that creates human tissue to replace animal testing in drug development, has raised $40 million in a second round of venture capital investment. The company, headquartered in ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, ...

De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times? The bone-modifying agents zoledronic acid, pamidronate, and denosumab have essential ...